Charles River Laboratories International, Inc. $CRL Stock Position Lowered by Versor Investments LP

Versor Investments LP lessened its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 52.4% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,802 shares of the medical research company’s stock after selling 3,086 shares during the quarter. Versor Investments LP’s holdings in Charles River Laboratories International were worth $559,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in the company. Vanguard Group Inc. lifted its position in shares of Charles River Laboratories International by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 5,887,175 shares of the medical research company’s stock valued at $1,174,374,000 after acquiring an additional 47,432 shares in the last quarter. Invesco Ltd. lifted its position in Charles River Laboratories International by 1.0% in the 3rd quarter. Invesco Ltd. now owns 1,249,178 shares of the medical research company’s stock worth $195,446,000 after buying an additional 12,035 shares in the last quarter. Bank of America Corp DE lifted its position in Charles River Laboratories International by 13.4% in the 3rd quarter. Bank of America Corp DE now owns 1,163,348 shares of the medical research company’s stock worth $182,017,000 after buying an additional 137,335 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in Charles River Laboratories International by 11.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,130,905 shares of the medical research company’s stock worth $176,909,000 after buying an additional 120,207 shares in the last quarter. Finally, Earnest Partners LLC lifted its position in Charles River Laboratories International by 0.8% in the 3rd quarter. Earnest Partners LLC now owns 1,006,724 shares of the medical research company’s stock worth $157,512,000 after buying an additional 8,467 shares in the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. TD Cowen cut their target price on shares of Charles River Laboratories International from $251.00 to $235.00 and set a “buy” rating for the company in a research report on Friday, February 20th. Evercore reiterated an “outperform” rating and issued a $220.00 target price on shares of Charles River Laboratories International in a research report on Friday, May 8th. UBS Group increased their target price on shares of Charles River Laboratories International from $170.00 to $175.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 25th. Barclays increased their target price on shares of Charles River Laboratories International from $210.00 to $220.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Finally, Citigroup increased their target price on shares of Charles River Laboratories International from $200.00 to $265.00 and gave the stock a “buy” rating in a research report on Friday, January 16th. Eleven research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $205.86.

Charles River Laboratories International Stock Down 3.6%

Charles River Laboratories International stock opened at $162.60 on Thursday. The company has a market capitalization of $7.83 billion, a P/E ratio of -43.24, a P/E/G ratio of 1.93 and a beta of 1.44. The firm’s fifty day simple moving average is $170.35 and its 200-day simple moving average is $182.83. The company has a current ratio of 1.36, a quick ratio of 1.03 and a debt-to-equity ratio of 0.90. Charles River Laboratories International, Inc. has a 1-year low of $132.58 and a 1-year high of $228.88.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share for the quarter, beating analysts’ consensus estimates of $1.96 by $0.10. The business had revenue of $995.83 million for the quarter, compared to the consensus estimate of $977.46 million. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. Charles River Laboratories International’s revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter last year, the firm earned $2.34 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. Sell-side analysts forecast that Charles River Laboratories International, Inc. will post 11.04 earnings per share for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.